Significant Milestones Fuel Development of Customized Therapeutics for Duchenne muscular dystrophy
BOSTON,MA / ACCESSWIRE / January 8, 2020 / Cure Rare Disease (CRD), the emerging, Boston-based nonprofit on a mission to develop precision medicine for rare diseases, is pleased to provide an annual review of its activities and accomplishments in 2019. Successful fundraising efforts have allowed CRD to accelerate their drug development plan, achieving significant milestones that are leading to the first in-man, customized therapeutic for Duchenne muscular dystrophy (DMD).
To view the full release with downloadable visuals and more, click here.
- Successful fundraising efforts have allowed CRD to accelerate their drug development plan.
- CRD has achieved significant milestones in developing the first in-man, customized therapeutic for Duchenne muscular dystrophy.
- Cure Rare Disease has a vision for 2020 that includes projected medical advancement and growth.
ABOUT CURE RARE DISEASE
Cure Rare Disease (CRD) is a Boston-based nonprofit biotechnology company founded by Rich Horgan, Blavatnik Life Science Entrepreneur-in-Residence at Harvard Business School who has witnessed three generations of his family affected by Duchenne muscular dystrophy, a fatal, neuromuscular disease. As anyone who is touched by a fatal, rare disease knows, time is of the essence. To overcome the obstacles inherent in the existing model of drug development, CRD has taken a new approach, forming an unprecedented collaboration with leading researchers and institutions nationwide in genetics, genomics, bioinformatics and biotechnology. Horgan and team are pioneering the development of a new platform for customized therapeutic treatments that can be applied to a range of rare, genetic diseases, and aim to inspire hope for a cure. Learn more at www.cureraredisease.org.
SOURCE: Cure Rare Disease
View source version on accesswire.com: